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Background: The transition from normal epithelium to adenoma and, to invasive carcinoma in the human colon is
associated with acquired molecular events taking 5-10 years for malignant transformation. We discovered CCAT1, a
non-coding RNA over-expressed in colon cancer (CC), but not in normal tissues, thereby making it a potential
disease-specific biomarker. We aimed to define and validate CCAT1 as a CC-specific biomarker, and to study CCAT1
expression across the adenoma-carcinoma sequence of CC tumorigenesis.
Methods: Tissue samples were obtained from patients undergoing resection for colonic adenoma(s) or carcinoma.
Normal colonic tissue (n = 10), adenomatous polyps (n = 18), primary tumor tissue (n = 22), normal mucosa adjacent
to primary tumor (n = 16), and lymph node(s) (n = 20), liver (n = 8), and peritoneal metastases (n = 19) were studied.
RNA was extracted from all tissue samples, and CCAT1 expression was analyzed using quantitative real time-PCR
(qRT-PCR) with confirmatory in-situ hybridization (ISH).
Results: Borderline expression of CCAT1 was identified in normal tissue obtained from patients with benign
conditions [mean Relative Quantity (RQ) = 5.9]. Significant relative CCAT1 up-regulation was observed in
adenomatous polyps (RQ = 178.6 ± 157.0; p = 0.0012); primary tumor tissue (RQ = 64.9 ± 56.9; p = 0.0048); normal
mucosa adjacent to primary tumor (RQ = 17.7 ± 21.5; p = 0.09); lymph node, liver and peritoneal metastases (RQ =
11,414.5 ± 12,672.9; 119.2 ± 138.9; 816.3 ± 2,736.1; p = 0.0001, respectively). qRT-PCR results were confirmed by ISH,
demonstrating significant correlation between CCAT1 up-regulation measured using these two methods.
Conclusion: CCAT1 is up-regulated across the colon adenoma-carcinoma sequence. This up-regulation is evident in
pre-malignant conditions and through all disease stages, including advanced metastatic disease suggesting a role
in both tumorigenesis and the metastatic process.
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Colon carcinoma (CC) is a common disease affecting
over a million people annually worldwide [1,2]. Major
advances in multi-modality therapy for CC over the past
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reproduction in any medium, provided the orability to identify, validate and apply clinically novel
disease-specific biomarkers may improve diagnostic ac-
curacy, disease staging, patient follow up and treatment
selection, and biomarkers stand to advance further posi-
tive treatment-related outcomes.
There are no clinically useful biomarkers currently
in widespread use for the diagnosis of CC. A stool-
based molecular assay for diagnosis was shown in a
recent study to have high diagnostic sensitivity and
specificity for CC [6,7]. Two tumor-related bio-
markers used as an adjunct to staging as well as for
post-treatment surveillance for disease recurrence areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Alaiyan et al. BMC Cancer 2013, 13:196 Page 2 of 11
http://www.biomedcentral.com/1471-2407/13/196Carcino- Embryonic Antigen (CEA) and Carbohydrate
Antigen 19-9 (CA-19-9) [8,9]. Neither CEA nor
CA19-9 is sufficiently sensitive or specific for CC sta-
ging or post-treatment surveillance [10,11].
A large number of genetic and epigenetic alterations
have been studied as potential biomarkers intended to
enable early disease detection, optimize cancer staging,
and facilitate accurate estimation of prognosis in CC
[12,13]. There is an increasing number of microRNA
fragments found in CC primary tumor tissues, metasta-
sis, and plasma [14-17] that may serve as biomarkers for
the detection of CC, estimating prognosis, and use in
the follow up of CC patients to assess treatment re-
sponse and disease state [18]. Changes in DNA me-
thylation patterns of specific genomic regions are
considered to be among the most common molecular
alterations in CC [19,20]. The transcriptome of CC has
also been studied showing about 0.5% of protein-coding
gene transcripts up-regulated in tumor tissue compared
to normal tissue [21]. Importantly, another transcrip-
tomic study identified one transcript that was over
expressed as much as 50-fold in CC over normal tissues
[22]. Despite advances in high throughput proteomic
characterization of aberrant protein expression and
disease-specific differentiation from normal colonic
tissue, very few biomarkers have been found to be cli-
nically useful and have attained widespread clinical
application [23,24].
Colon Cancer Associated Transcript 1 (CCAT1) is a
2628 nucleotide-long, non-coding RNA recently dis-
covered using Representational Difference Analysis
(RDA), cDNA cloning, and rapid amplification of
cDNA ends (RACE) [25]. CCAT1 is located in the
vicinity of c-MYC, a well-known transcription factor.
Preliminary experiments showed CCAT1 up-regulation
in tumor cell lines and tissues obtained from CC
patients. Studies in human tissues showed minimal ex-
pression in normal liver and small bowel tissue; how-
ever, no CCAT1 expression was detected in many
other human tissues tested. The location of CCAT1
on chromosome 8q24.21 is significant since this area
was described before as a “hot spot” harboring mul-
tiple genetic alternations in both colon and prostate
cancer [26,27].
The current study was based on initial exploratory
findings of increased CCAT1 expression in colon ade-
nocarcinoma but extremly low transcript expression in
normal human tissue [25]. The principal aim of this
study was to further characterize expression of this novel
molecular marker for CC. CCAT1 expression is investi-
gated across the spectrum of CC carcinogenesis in the
current study: from normal tissues, through adenoma, as
well as invasive carcinoma, to include lymph node as
well as distant metastasis.Methods
Patients
This is a prospective pathological and molecular study
of primary colon and appendecial adenoma, adenocar-
cinoma, regional nodal tissue and distant metastasis
(liver and peritoneal) from patients undergoing resection
of the primary tumor, regional lymph nodes, and/or me-
tastasis, as well as patients undergoing colon resection
for benign conditions. The study was approved by the
Institutional Review Board (Helsinki Committee; Proto-
col 391-04-08-06). Patients with a diagnosis of primary,
or metastatic (Clinical UICC-AJCC Stage I-IV) CC or
patients scheduled to undergo colon resection for benign
conditions, were included. To be eligible for study pa-
tients had biopsy-proven, primary CC or adenoma, had
a benign condition requiring colon resection, were
>18 years-of-age, and capable of providing informed
consent. Written informed consent was obtained from
all participants.Tissue procurement
Tissues were obtained from random areas of the resected
colon of patients with benign conditions, from the pri-
mary lesion (adenoma or invasive adenocarcinoma), and
from normal appearing mucosa adjacent to the primary
tumor site. Lymph nodes were obtained from the meso-
colon after sufficient tissue was submitted for standard
histopathological analysis. Liver metastasis were obtained
from patients undergoing hepatic resection and peritoneal
metastasis were obtained from patients undergoing cyto-
reductive surgery and hyperthermic intra-peritoneal
chemotherapy. Immediately following surgical resection,
the specimen was delivered fresh to the Department of
Pathology, where, under the supervison of an attending
pathologist, a small portion of resected tissue was snap
frozen in liquid nitrogen for future RNA extraction. One
hundred twenty tissue samples from 94 study subjects
were collected. Seven patients [(peritoneal (n = 6), and
liver metastases (n = 1)] were excluded because RNA
extracted from their tissue was of low quality, insufficient
for qRT-PCR, leaving 113 tissue samples from 87 patients
for analysis.
Total RNA isolation from tissues
Total RNA was extracted using the miRvanaW isolation kit
(Ambion Inc., Austin, TX) in accordance with manu-
facturer instructions. Weighed tissues were thoroughly
crushed on dry ice and disrupted with 1 ml/50-100 mg tis-
sue, denaturizing lysis buffer using a polytron tissue
homogenizer. RNA concentration was measured with
NanoDropW Spectrophotometer (ND-100, NanoDrop
Technologies, Wilmington, DE) and stored at -80°C until
further use.
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Following DNase treatment, cDNA synthesis was per-
formed using random primer (Roche Diagnostics GmbH,
Mannheim, Germany) added to 10 μl of RNA. After incu-
bation, 1 μl of reverse transcriptase (SuperScript II Re-
verse Transcriptase 200 U/μl, Invitrogen, Carlsbad, CA)
was added. The cDNA was stored at -20°C until used for
qRT-PCR.
Real time quantitative PCR
Primers used were: CCAT1 (custom designed by Applied
Biosystems Inc., Foster City, CA):
CCAT1-Forward – TCACTGACAACATCGACTTT
GAAG
CCAT1-Reverse - GGAGAAAACGCTTAGCCATACAG
CCAT1-Probe - Fam-TGGCCAGCCCTGCCACTTAC-
ZNA-4-BAQ-1
GAPDH (probe dye: VIC-MGB 4326317E-0411007) was
used as a control gene.
CCAT1 RNA was normalized to GAPDH-RNA con-
tent using ABI 7500 SDS software, v1.2.2 (Applied
Biosystems Inc., Foster City, CA). Positive and negative
controls, as well as samples with no DNA were included
in every qRT-PCR experiment. PCR reactions were per-
formed using ABI qRT-PCR thermocycler (7500 Real
Time PCR System, Applied Biosystems Inc., Foster City,
CA). The qRT-PCR program was run for 40 cycles, fol-
lowing an initial incubation at 95°C, 10 min. Each cycle
consisted of 95°C × 15 sec. and 60°C × 1 min.
In situ hybridization
Fluorescein isothiocyanate (FITC) labeled CCAT1 probe
was used for in situ detection of CCAT1 in formalin
fixed paraffin embedded (FFPE) colon tissues in accor-
dance with a standardized protocol [28]. Briefly, the de-
paraffinized colon tissue slides were treated with protein
K (24 g/ml) for 30 min. at room temperature. After
washing with water, the slides were hybridized with
600 nM CCAT1 probe at 55°C for 90 min in a humidity
chamber. The slides were then washed in Tris-Buffered
Saline Tween-20 (TBST) for 25 min at 55°C with agita-
tion to remove excess CCAT1 probe. Pre-diluted AP
conjugated Anti-FITC antibody (Santa Cruz Biotechno-
logy, Inc., Santa Cruz, CA) was applied onto the tissue
samples for 30 min at room temperature followed by
color development using 5-Bromo-4-chloro-3-indolyl
phosphate (BCIP) as a substrate.
Statistical analysis
Summary statistics were obtained using established
methods. Associations between categorical factors werestudied with Fisher’s exact test or Chi-squared test, as ap-
propriate. Continuoues variables between study groups
were compared using the T-test (two-sided). Statistical
analysis was performed using IBM-SPSSW statistical pac-
kage Version 19.0 (SPSS Inc. Chicago, IL). A p value < 0.05
was considered significant.Results
Tissue samples were obtained from patients (n = 94)
undergoing surgery for benign inflammatory conditions,
adenomatous polyps or various stages of CC. In patients
with distant metastatic disease (n = 34), one liver (1/9)
and six (6/25) peritoneal metastases were excluded as in-
dicated above. Overall, RNA was successfully extracted
from 113 of 120 samples (94.2%) obtained from 87 pa-
tients and found to be suitable for analysis.CCAT1 expression in benign inflammatory colonic tissues
RNA was extracted from patients with various non-
malignant conditions (n = 10, Table 1). Using comercially
available normal colonic RNA as a calibrator, mean
CCAT1-RQ was 5.9 ±5.6. Compared to normal colonic
RNA, there was 1-5 fold up-regualtion of CCAT1 ex-
pression in 70% (7/10) of inflammed colonic tissue.
Interestingly, in three of these 7 patients, one with per-
forated appendicitis and an inflammatory mass, and two
with severe complicated diverticulits requiring emergent
surgical intervention, inflammatory colonic tissue CCAT1
was expressed to an even greater degree: 11-13 fold rela-
tive to normal colonic tissue RNA.
CCAT1 expression in normal colonic mucosa adjacent to
the primary colon adenocarcinoma
In a previous study [22], we obserevd high levels of
CCAT1 expression in histologically normal appearing
colonic mucosa obtained from patients with primary
CC. We therefore analyzed normal-appearing mucosa
sampled in the vicinity of the tumor in 16 of 22 patients
with primary CC. Mean (±SD) RQ for normal tisssues
was 17.7 ± 21.5. Significant CCAT1 up-regualtion (>10%
of tumor tissue) was observed in 63% (10/16) of peri-
tumoral normal tissue. To rule out contamination of
normal mucosa by cancer cells shed at time of surgery
or tissue handling after CC resection, we studied CCAT1
expression in tumor and adjacent normal tissues by
in-situ hybridization and compared CCAT1 expression
intensity to normal colonic tissue obtained from patients
with no known colonic disease operated for trauma. The
qRT-PCR results obtained in this study were confirmed
by in-situ hybridization staining (Figure 1), thereby ma-
king contamination as a source of false positive finding
very unlikely.
Table 1 Clinical and pathological charactaristics of patients with inflammatory conditions participating in the study
N Sample number Diagnosis Age Gender Procedure RQ
1. 814 Ischemic colitis 47 Male Subtotal colectomy 2.02
2. 595 Perforated appendecitis 31 Male RT colectomy 15.338
3. 827 Diverticulitis 73 Male Sigmoid resection 14.929
4. 854 Diverticulitis 33 Male Sigmoid resection 13.881
5. 331 Diverticulitis 64 Female Sigmoid resection 3.004
6. 351 Perforated volvulus 69 Male Sigmoid resection 2.154
7. 537 Diverticulitis 49 Female Sigmoid resection 1.162
8. 594 Diverticulitis 54 Female Sigmoid resection 5.54
9. 704 Diverticulitis 36 Male Sigmoid resection 1.402
10. 803 Diverticulitis 67 Female Sigmoid resection 4.88
11. Colon NN AmbionW * Trauma unknown 1
RQ = Relative Quantity of CCAT-1 RNA.
* commercially available RNA mixture.
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Patients with adenomatous polyps (n = 18) >10 mm in
size who failed endoscopic resection, underwent colec-
tomy. Clinical and histopathological details are outlined
in Table 2. There were 6 (33%) tubular adenomas,
2 (11%) villous adenomas, and 10 (56%) tubulovillous
adenomas. Low- and high-grade dysplasia was diagnosed
in 5 (28%) and 13 (72%) patients, respectively. No sta-
tistically significant correlation was observed between
adenoma sub-type (p = 0.24) or degree of dysplasia
(p = 0.68), and CCAT1 expression. Mean CCAT1 RQ
was 176.9 ± 148.7. CCAT1 was significantly (>10 fold)
up-regulated in 17 of 18 (94%) adenomatous polyps
studied. Of these 17 positive samples, CCAT1 had very
high expression (>100 fold) in 11 of 18 (61%). The diffe-
rence between normal (inflammatory) tissues and pre-
malignant tissues is demonstrated in Figure 2.
The expression of CCAT1 in primary tumor tissue of
patients with adenocarcinoma of the colon
As CCAT1 was first shown to be up-regulated in human
CC tissue [22], we anlayzed a new patient cohort with
AJCC Stage I-III CC (n = 22, Table 3). Mean RQ for
tumor tisssues was 64.9 ± 56.9. There were 12 female
patients with slightly higher values of CCAT1 expres
sion (RQ = 69.2 ± 64.5) than that found in male patients
(RQ = 41.4 ± 39.2; p = 0.29). There was higher expression
of CCAT1 in patients ≥ 60 years of age (RQ = 75.8 ± 72.8
vs. 40.4 ± 36.5 for patients <60 years of age, p = 0.17).
There was no statistically significant correlation between
T-Stage, N-Stage or AJCC Stage and CCAT1 expression.
Further, primary tumor grade, mucin production, lympho-
vascular or perineural invasion did not correlate signi-
ficantly with CCAT1 expression in primary CC. There
was, however, a trend toward higher CCAT1 expression inright-sided (n = 9; RQ = 81.7 ± 74.1) versus left-sided tu-
mors (n = 13; RQ= 42.2 ± 42.3, p = 0.13). Overall, CCAT1
up-regulation of 5-fold or higher compared to normal
colon was seen in 20/22 (90.1%) of CC samples.The expression of CCAT1 in lymph node metastasis of
patients with adenocarcinoma of the colon
Lymph nodes (LNs) from patients undergoing surgery for
CC (n = 10) were sectioned in half, with one half of the
node undergoing standard histopathological examination,
and the other half of the node snap frozen for subsequent
analysis. There was no CCAT1 expression in the LNs
obtained from patients with benign inflammatory condi-
tions (n = 6, Figure 3). CCAT1 was highly up-regulated in
all metastatic LNs having a mean RQ= 11,414.5 ± 12,672.9
compared to a mean RQ of 12.4 ± 21.3 for benign LNs
(p = 0.019) and compared to lymph nodes not harboring
metastasis by histopatholgical examination obtained from
the same patients (n = 10). The RQ was 157.2 ± 218.2 for
the histologically benign LNs (p = 0.021). In three patients
(patients #612, #655, and #698) we had matched tissues
of primary tumor and lymph node metastasis. CCAT1
expression was up-regulated in all three primary tumors
(Table 3).CCAT1 expression in liver metastasis of colorectal cancer
origin
Representative tissue samples obtained from resected CC
liver metastasis were analysed (n = 8). All samples were
obtained from patients treated with systemic therapy be-
fore resection of liver metastasis. CCAT1 was up-regulated
in 6 of 8 (75%) of tissues studied. Mean RQ for normal
tisssues was 119.2 ± 138.9.
3281/08   3-1 N CCAT1-12 3281/08   8-2 T CCAT1-125723/08 AD3 MN CCAT1-12
a. Normal colon b. Normal colon 
adjacent to tumor
c. adenocarcinoma
Figure 1 CCAT1 expression analyzed by in-situ hybiridization. In situ hybrdization of CCAT1 was analyzed in normal colonic tissue (a), normal
mucosa adjacent to the primary tumor site (b) and in primary adenocarcinoma of the colon (c). Samples a and b were obtained from the same
patient (T877). The probe sequence and topographic location within the CCAT1 gene are outlined in the lower part of the figure.
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carcinoma and appendiceal neoplasms
Peritoneal spread of CC may have a different mechanism
of dissemination than that of visceral CC metastasis. Ade-
nocarcinoma and other neoplasms originating from the
vermiform appendix may also have both different patho-
genesis and different molecular features than CC. There-
fore, we elected to study CCAT1 expression in tissues
obtained from 19 patients with peritoneal metastasis of
colon (n = 14) and appendiceal origin (n = 5). All patients
received systemic therapy before cytoreductive surgery.
There was low CCAT1 expression in 20% (1/5; mean RQ
= 0.99 ± 1.9) of appendiceal neoplasms (4 adenocarci-
nomas and one pseudomyxoma peritonei), while it was
upregulated in 50% (7/14; mean RQ= 816.3 ± 2,736.1) of
peritoneal metastasis of colonic origin. This difference wasnot statistically different (p = 0.21) mainly due to large
varibility in the CCAT1 expression of peritoneal metasta-
sis of colonic origin.
Discussion
The sequential progression of colon tumorigenesis pro-
vides an excellent system to assess promising biomarkers
for colon cancer screening and early detection. This
adenoma-carcinoma sequence leading to CC is well de-
scribed, and is characterized by multiple genetic and epi-
genetic events [29]. However, to the best of our knowledge,
there is not a single molecule uniformly up-regulated in all
phases of CC development.
Colon Cancer Associated Transcript 1 (CCAT1) is a
unique transcript up-regulated in CC compared to nor-
mal human tissues [25]. Its role in tumorigenesis has yet
CCAT
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Table 2 CCAT1 expression in adenomatous polyps
Sample number Diagnosis Dysplasia Age Gender RQ
1016P1 TA LGD 66 F 102.32
1030P1 TVA HGD 40 M 154.34
1052P1 TA HGD 75 F 258.50
1065P VA HGD 75 M 11.03
1079P TA HGD 23 M 1.80
597P TVA HGD 40 F 116.08
608P2 TVA HGD 64 M 132.88
619P TA LGD 72 F 40.93
626P TVA HGD 33 M 94.42
760P9 TVA HGD 73 M 180.52
778P TVA HGD 64 F 67.65
809P TVA HGD 71 F 189.49
844P1 TVA HGD 78 M 58.57
872P TA HGD 67 F 382.15
881P TVA HGD 73 F 334.07
887P1 TVA HGD 65 M 554.10
932P VA LGD 58 F 88.04
935P1 TA LGD 72 M 448.82
RQ = Relative Quantity of CCAT1 RNA.
TA = tubular adenoma, VA = villous adenoma, TVA = tubulovillous adenoma.
LGD = low grade dysplasia, HGD = high grade dysplasia.
M =male, F = female.
IMC = intra-mucosal carcinoma.
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up-regulation of CCAT1 in over 90% of colonic adeno-
carinomas, with relatively little or no transcript expres-
sion in a panel of normal human tissues [25]. We
identified slightly higher expression of CCAT1 in colonic
tissues obtained from patients with benign colonic disor-
ders compared to normal, non-inflamed colonic tissue.
This slight up-regulation was more prominent in the tis-
sue samples of patients with inflammatory conditions
and reached a 15-fold increase in patients with severe
colonic inflammation. If this observation can be repli-
cated in chronically inflamed colonic tissues such as
those obtained from inflammatory bowel disease pa-
tients, this may suggest a role for CCAT1 in neoplastic
transformation often observed in chronically inflamed
tissues.
In this study we have shown again that CCAT1 is up-
regulated in most (20/22) primary tumor tissues. Inter-
estingly, CCAT1 was also up-regulated, albeit to a lesser
degree, in many of the histologically normal appearing
mucosa samples adjacent to the primary tumor site. This
may be caused by a contamination of nearby cancer cells
shed during surgery or during tissue handling. In to
order address this potential issue of cellular contami-
nation, we used formalin fixed paraffin-embedded tissue
of one of the study subjects showing CCAT1 up-1 expression
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ssion in the adenoma-carcinoma sequence. The log RQ of CCAT1
olon adjacent to the tumor site (Normal Adj.), adenomatous polyps,
r-Mx), and peritoneal metastasis (Peritoneal-Mx). Mean RQ and
expression was compared to normal colon. * p < 0.09, ** p = 0.012,
Table 3 Anatomical and Histological characteristics of tumer samples
Sample Anatomic location AJCC stage Grade Mucin LVI BVI Neural Age (years) Gender RQ-T RQ-N
612 LT 3 2 NO NO NO NO 70.00 F 7.01 71.26
655 LT 3 2 NO NO NO NO 73.00 F 5.91 0.021
662 LT 3 2 NO NO NO NO 71.00 M 18.15 2.65
681 LT 3 2 NO NO NO NO 54.00 F 50.24
698 LT 3 2 NO NO NO NO 60.00 M 8.46
712 LT 3 2 NO NO NO YES 40.00 M 83.11 52.60
759 LT 2 2 NO NO NO NO 71.00 M 16.33 10.345
760 RT 3 2 YES NO NO NO 73.00 M 21.01 2.27
766 LT 3 2 NO NO NO NO 70.00 F 139.49 7.04
781 RT 2 2 NO NO NO NO 42.00 F 82.03 0.35
809 RT 2 2 YES NO NO NO 70.00 F 171.37 1.01
828 LT 4 3 NO YES YES YES 53.00 M 22.15 35.24
829 LT 3 2 NO NO NO NO 46.00 M 94.81 27.15
838 RT 2 2 YES NO NO NO 46.00 M 0.00
844 RT 2 2 YES NO NO NO 78.00 M 108.38 3.68
853 LT 3 2 NO NO NO NO 50.00 F 0.00
861 RT 3 2 NO NO NO NO 74.00 F 194.12
881 RT 3 3 NO YES NO YES 72.00 F 76.37 0.99
883 LT 3 2 NO NO NO NO 53.00 F 41.41 19.55
887 RT 2 2 NO NO NO NO 56.00 F 80.45 37.77
905 LT 2 2 NO NO NO NO 53.00 F 62.21 11.03
1013 RT 2 2 NO NO NO NO 87.00 M 145.11
AJCC = American Joint Committee on Cancer.
BVI = blood vessel invasion, LVI = lymph vessel invasion, neural = neural invasion.
Mucin = presence of mucin within or around the tumor.
RQ-T = relative quantity of CCAT1 expression in tumor tissue.
RQ-N = relative quantity of CCAT1 expression in adjacent normal tissue.
M =male, F = female.
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gree in the adjacent normal tissue (T877) by qRT-PCR,
and analyzed transcript expression by in-situ hybridization.
Good correlation was observed between the qRT-PCR
findings and the in-situ hybridization findings indicating
that this is a real biological phenomenon rather than a
false positive finding related to local tumor cell contami-
nation. Currently we are in the process of performing
in-situ hybridization on a large cohort of colon cancer
patients to further study this phenomenon.
The up-regulation of a tumor marker in histologically
normal-appearing tissue is a complex matter, a “double-
edged sword.” On the one hand, this finding may provide
a powerful tool to predict future risk of colon cancer by
studying biomarker expression in random colonic muco-
sal biopsies in screening or high-risk populations. On the
other hand, biomarker expression in clinically disease-free
patients may be interpreted as a false positive finding,
which amounts to reduced diagnostic accuracy of the test.
If co-expression of CCAT1 and DNA-methylation abnor-
malities shown to appear in early phases of the adenoma-carcinoma sequence [30] can be found, this co-expression
may be more predictive of adenoma-carcinoma sequence
progression, and will serve as the basis for development of
risk reduction or early curative intervention strategies.
A clinically important stage in the adenoma-carcinoma
process is the formation of an adenomatous polyp. We
analyzed tissue from adenomatous polyps for CCAT1
expression. We restricted our analysis to polyps larger
than 10 mm in diameter, in order not to compromise
histopathological diagnosis. The in-situ technique for
CCAT1, described earlier [28], may provide a tool for fu-
ture analysis of CCAT1 expression in smaller polyps,
and for differential diagnosis of hyperplastic and aden-
omatous polyps, namely those with uniformly benign
and those with possibly malignant natural history. We
observed CCAT1 to be up-regulated in all but one of
the 18 adenomatous polyps studied. In 61% of these ad-
enomatous polyps the transcript expression exceeded
100-fold relative to that of normal colon tissue. This
observation provides supportive evidence of a role of
CCAT1 in the early neoplasia (adenoma formation) stage
CCAT1 expression
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Figure 3 A logarithmic scale of relative quantity (RQ) of CCAT1 expression in lymph nodes. The log RQ of CCAT1 expression is shown for
benign lymph nodes (white rectangle), lymph nodes without metastasis by histopatholgical examination (gray rectangle), and for lymph nodes
with metastasis from the same colon cancer patients (black rectangle). The colon cancer cell line HT29 was used as positive control and a
commercially available normal lymphatic tissue was used as a calibrator (LN_NN-Ambion).
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CCAT1 expression in adenoma significantly exceeding
that of carcinoma further supports this hypothesis, as it
points to a down-regulating effect on CCAT1 expression
once malignant transformation is attained.
CCAT1 up-regulation of 5-fold or higher compared to
normal colon. Transcript up-regulation was seen in
90.1% of malignant primary tumor samples obtained
from patients with Stage I-III colon adenocarcinoma.
The fact that this non- coding RNA is located on
chromosome 8q24.21, a “hot spot” for many cancer-
related single nucleotide polymorphisms (SNPs), sup-
ports a role for CCAT1 in the tumorigenesis of colon
carcinoma.
Current histopathological nodal staging techniques may
overlook occult lymph node metastases amounting to
pathological under-staging and under-treatment. Many
investigators have tried to improve upon lymph node
staging in patients with colon cancer [31-34]. We analyzed
lymph nodes from patients with colon cancer having ob-
vious macro-metastasis by standard histopathological
staging for CCAT1 expression and compared this expres-
sion to that of negative lymph nodes by histopathology
obtained from the same patients and to that of benign
lymph nodes for patients without colon cancer. CCAT1
was highly up-regulated (over 100 fold) in all 10 metastatic
lymph nodes studied. Such exceedingly high expression of
CCAT1 may suggest an important role of this unique
non-coding RNA in regional lymphatic and nodal dissem-
ination of colon adenocarcinoma. Furthermore, this fin-
ding may be applied clinically for the detection of occultmetastatic disease in seemingly disease-free regional
lymph nodes of patients undergoing surgical resection of
colon cancer with curative intent. This would improve
staging accuracy and individualized treatment planning,
specifically adjuvant systemic therapy in patients with no-
dal disease.
Two of the most common sites of metastatic spread of
colon adenocarcinoma are the liver and peritoneum.
Therefore, we included patients operated on for treat-
ment of metastatic disease to these organ sites in our
study. Unfortunately, all patients were previously treated
by systemic therapy; therefore, treatment-related altera-
tions in CCAT1 expression cannot be excluded in these
pre-treated patients. However, the practical reality is that
access to tissue of naïve (previously untreated) patients
with colon cancer metastatic to the liver or peritoneum
is limited, as it is a distinctly rare clinical scenario since
most patients are treated, according to our evidence-
based guidelines, with systemic therapy before surgery
for metastatic disease.
Taking this potential bias into account, we showed that
CCAT1 was up-regulated in liver as well as in peritoneal
metastasis of colon cancer patients. The variability bet-
ween the results may be due to the therapeutic efficacy of
the previous chemotherapy, or may reflect true biological
variability in CCAT1 expression. The only way to study
this definitively is to obtain metastatic tissue before and
after systemic therapy administration and demonstrate a
decrease in CCAT1 expression in systemic treatment res-
ponders. Another non-coding RNA up-regulated in liver
metastasis as well as in many cancer types is H19 [35].
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in histologically normal-appearing liver surrounding me-
tastasis [36]. This correlates, in part, with our observation
of CCAT1 up-regulation in normal colonic tissues adja-
cent to the primary tumor site.
Stein et al, recently discovered another transcript with
potential clinical relevance, Metastasis-Associated in Colon
Cancer-1 MACC [37]. MACC1 has a regulatory role in the
HGF/Met signaling pathway which has an important role
in cell migration, invasion, and metastatic potential [38].
MACC1 expression in the primary tumor and in plasma
of CC patients was shown to be an independent risk fac-
tor for metastasis [38,39]. The prognostic significance of
CCAT1 is remains unclear. We are in the process of study-
ing a large cohort of patients with early CC for level of
CCAT1 expression, and will correlate expression of this
transcript with overall survival.
Serum markers in clinical use for CC (CEA and CA
19-9) are neither sensitive nor specific [40]. Therefore
the most common application of CEA and CA-19-9 is to
monitor patients for recurrent disease following treat-
ment of CC or to monitor response to systemic therapy
[41]. If the measurement of CCAT1 levels in the plasma
of CC patients should prove both feasible and repro-
ductive, then it may be added to the current serum
markers to monitor disease behavior and patient re-
sponse to treatment.
Another interesting observation is that CCAT1 expres-
sion is higher in patients with peritoneal metastasis origin-
ating from colon cancer compared to peritoneal surface
malignancy of appendiceal origin. The results did not
reach statistical significance in this particular comparison,
due to the large variability of transcript expression ob-
served in the colon cancer patients. Nevertheless, we think
that further investigation is warranted because appendi-
ceal adenocarcinoma, as do some colon adenocarcinomas,
demonstrates preferential spread to the peritoneal surface
rather than to solid visceral organs.
The expression of CCAT1 in tissues of all stages of the
adenoma-carcinoma sequence of colorectal cancer to-
gether with our previous preliminary observations [22]
that CCAT1 can be amplified from the blood and stool
samples of patients with CRC point to a promising, novel
biomarker for CRC. CCAT1 can be used to enhance
pathological staging in borderline cases by in-situ hybri-
dization; it can be used in an RNA-based stool assay for
the screening and early detection of CRC, and in blood
tests for the diagnosis and follow-up of CRC patients.
In summary, we studied CCAT1 expression in human
biospecimens spanning the biological spectrum of benign,
pre-malignant and malignant colonic tissues and demon-
strated CCAT1 up-regulation, which peaked in tissues
from adenomas and colon adenocarcinoma lymph node
metastases.Conclusions
We conclude that CCAT1 is up-regulated in the colon
adenoma-carcinoma sequence. This up-regulation is evi-
dent in pre-malignant conditions and through all disease
stages, including advanced metastatic disease suggesting
a role in tumorigenesis and the metastatic process.
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